Rubella Diagnostic Testing Market

Market Overview

The global rubella diagnostic testing market size was valued at USD 4.8 billion in 2023 and is projected to reach USD 7.4 billion by 2032, registering a CAGR of 4.9% during the forecast period (2024-2032). The increasing number of Rubella diagnostic tests, combined with government attempts to decrease infection rates and advancements in point-of-care diagnosis, is expected to drive market expansion throughout the projection period. 

Rubella diagnostic testing identifies and detects the presence of the Rubella virus or antibodies produced in response to Rubella infection in clinical specimens collected from people suspected of having Rubella. Rubella, commonly known as German measles, is a contagious viral infection with a striking red rash. Rubella diagnostic testing is crucial for verifying illness, managing patients, and preventing spread.

In addition, government initiatives to combat the rubella virus, rising rubella occurrences, and developing enhanced point-of-care diagnostic technologies are all driving expansion in the market under consideration. Individuals are becoming more aware of the importance of speedy rubella diagnostics due to increased government initiatives pushing the market. Additionally, the development of point-of-care diagnostics for rubella diagnosis is propelling the growth of the studied industry. Thus, the market is likely to rise significantly throughout the forecast period due to government measures to combat the rubella virus, rising rubella occurrences, and the development of new point-of-care diagnostic technologies. However, a lack of awareness in developing countries may delay expansion throughout the research.

Highlights

• Enzyme immunoassay (EIA) holds a significant market share through testing techniques.
• Hospitals influenced the market growth by application.

Market Dynamics

Global Rubella Diagnostic Testing Market Drivers

Government Initiatives for Rubella Elimination

Government Rubella elimination initiatives substantially impact the need for diagnostic testing and the global Rubella diagnostic testing market. These initiatives aim to eliminate Rubella through extensive vaccination campaigns, surveillance, and public health measures. The Measles and Rubella Partnership (MR&P), formerly the Rubella Initiative, is a global initiative to save lives through vaccines. By 2023, MR&P hopes to save 50 million lives by providing access to vital vaccines. To eliminate measles and Rubella by 2023, the MR&P has requested additional financing of USD 0.19 per capita per year from national governments and partners to implement solutions. The MR&P has also called for enhanced collaboration, proactive attempts to close immunity gaps, and the implementation of novel techniques. The effort helps countries organize immunization campaigns, develop surveillance systems, and increase laboratory capacity for Rubella diagnosis.

Furthermore, the World Health Organization (WHO) has developed a Plan of Action to ensure the long-term elimination of measles, Rubella, and congenital rubella syndrome (CRS) from 2018 to 2023. India aims to eliminate measles and Rubella by 2023, which includes obtaining at least 95% coverage with two doses of the measles- and rubella-containing vaccination (MCV2; RCV2). While the United States aims for 95% rubella vaccination, only 93.1% of kindergarteners received the MMR vaccine between 2022 and 2023, putting approximately 250,000 children at risk. 

Global Rubella Diagnostic Testing Market Restraints

Decline in Disease Incidence in the Vaccinated Population

Rubella incidence has decreased dramatically in nations with strong Rubella vaccination coverage, such as the United States, Canada, and many European countries, since routine Rubella vaccination was included in national immunization programs. As a result, Rubella outbreaks are infrequent, and diagnostic testing is less necessary than in areas with lower vaccination coverage or endemic Rubella transmission. According to the CDC, the number of rubella infections in the United States has declined drastically since the rubella vaccination was introduced in 2023, with fewer than 10 cases reported yearly.

In 2023, many European countries had high Rubella vaccination coverage, with Poland reporting 263 instances of Rubella, nearly the total number of cases documented in Europe that year. Surveillance statistics from European countries show that Rubella incidence has declined in recent decades, with infrequent outbreaks occurring in sensitive groups or unvaccinated areas. As fewer Rubella cases arise in vaccinated populations, the requirement for diagnostic testing for acute Rubella infection decreases. Diagnostic laboratories may see a reduction in testing volumes and fewer requests for Rubella serology or molecular testing.

According to the CDC, recorded rubella cases decreased by 81% globally between 2012 and 2022, from 93,816 to 17,407 cases. In 2022, 98 nations (51%) have confirmed rubella elimination, up from 43% in 2019. This significant decline in Rubella incidence indicates the effectiveness of vaccination campaigns and highlights the success of Rubella control activities in many parts of the world.

Global Rubella Diagnostic Testing Market Opportunity

Enhanced Surveillance and Monitoring Program

In areas where Rubella is endemic or vaccination coverage is low, there is a potential to develop Rubella surveillance systems to improve illness identification and response. Countries in Sub-Saharan Africa, Southeast Asia, and parts of Latin America may encounter Rubella control issues due to low resources, infrastructure shortages, and conflicting public health goals. Improving laboratory-based surveillance, case reporting methods, and data-sharing platforms can help discover Rubella cases, track disease trends, and execute focused control actions. The World Health Organization (WHO) manages global Rubella surveillance via the Measles and Rubella Laboratory Network (LabNet) and the Global Measles and Rubella Laboratory Network (GMRLN). These networks provide laboratory-based Rubella surveillance, including case confirmation, genotyping, and vaccine efficacy monitoring. 

Furthermore, epidemiological studies conducted in Rubella-endemic areas or populations with low vaccination coverage give essential information about Rubella transmission dynamics, susceptibility patterns, and risk factors. These studies influence monitoring priorities, outbreak response methods, and immunization campaigns, directing resources and interventions to areas in greatest need. 

Thus, improved surveillance systems may raise demand for Rubella diagnostic tests, such as serological and molecular assays, to confirm suspected cases, track illness trends, and check Rubella elimination status. Furthermore, enhanced surveillance methods help to increase data quality, completeness, and timeliness, increasing the dependability and utility of Rubella surveillance data for decision-making and programmatic planning.

Regional Analysis

The global rubella diagnostic testing market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global rubella diagnostic testing market shareholder and is estimated to grow at a CAGR of 4.6% over the forecast period. The North American region is predicted to develop significantly over the forecast period due to essential market participants, significant government programs, and technical advancements related to this condition's appropriate and prompt diagnosis. Furthermore, considerable government measures are causing a decrease in rubella cases across the country. For example, in January 2022, the Government of Canada reported no new cases of measles or Rubella in week 52 of 2021, and there are no active cases of measles or Rubella in Canada today. Canada recorded one case of Rubella in 2023, with the last case reported in September 2023. In 2024, 48 measles cases and one congenital Rubella syndrome/infection were documented. Thus, the government's initiatives to eradicate Rubella through appropriate diagnosis support market expansion.

Similarly, the Centers for Disease Control and Prevention (CDC) announced in January 2021 that Rubella is no longer endemic in the United States. According to the CDC, implementing a high-quality surveillance system is essential for eliminating Rubella in the North American region. The regional administration has established routine immunization for children, which, when supplemented with effective diagnostic campaigns in countries with high case and death rates, is a critical public health strategy for reducing worldwide measles fatalities.

Furthermore, introducing new technologies hastened the region's investigated industry's expansion. For example, an article published in the Journal of Virology Methods in May 2022 stated that the COVID-19 pandemic has disrupted rubella vaccination services all over the world, resulting in an increased immunity gap, and RV genotype surveillance is a critical component of monitoring progress toward rubella elimination and eradication goals. This RuV multiplex assay will provide sensitive and accurate test findings quickly. Such research and the development of new diagnostics are fueling the region's market expansion. 

Asia-Pacific is anticipated to exhibit a CAGR of 5.3% over the forecast period. The growing population and improved healthcare facilities with simple access are expected to drive market expansion. Furthermore, increased demand for lower healthcare costs will drive market expansion. Asia Pacific's dominant countries include India, China, and Japan, owing to significant market participants in the region. Furthermore, Asia Pacific has seen the most robust growth in the rubella diagnostics testing market, which is expected to continue at this rate. Moreover, a lack of awareness in a developing country and government measures will likely keep the market growing.

Europe holds a significant market share. Vaccination regulations, healthcare infrastructure, and disease epidemiology all impact Europe's rubella diagnostic testing industry. Many European countries have long-standing Rubella vaccine regimens as part of their national immunization schedules. For example, the European Centre for Disease Prevention and Control (ECDC) recommends Rubella vaccination as part of a standard pediatric immunization schedule, commonly given as a combined measles, mumps, and Rubella (MMR) vaccine. Countries such as Germany, France, and the United Kingdom have excellent vaccine coverage rates, which help to limit Rubella transmission and avoid congenital Rubella syndrome (CRS). 

Segmental Analysis

The global rubella diagnostic testing market is segmented based on testing technique, application, and region.

The market is further segmented by testing technique into Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), and Fluorescent Immunoassay (FIA).

The enzyme immunoassay category now has most of the Rubella diagnostic testing market share. Enzyme immunoassay (EIA) reagents and devices are used to detect the presence or concentration of an antigen, which is then applied to epidemiological disease detection. It includes several enzymes, such as alkaline phosphatases and glucose oxidase. The rubella virus can live in the bloodstream for years before being destroyed by antibodies produced by the immune system. IgM testing is the most common method for commercial enzyme immunoassay (EIA) kits. Because all matched specimens tested from patients with acute rubella infection showed a considerable increase in antibody levels, the enzyme immunoassay (EIA) can also be used to detect acute infections. The increasing prevalence of infectious disorders such as Rubella is the primary reason for the rise of the enzyme immunoassay (EIA) segment.

Furthermore, the test's feasibility and accuracy also contribute to the segment's expansion. For example, an article published by mSphere in July 2021 stated that measles and Rubella are two of the most globally important vaccine-preventable diseases (VPD) and that measuring antibodies to measles and rubella viruses in samples collected from serosurveys can play an important role in estimating population immunity and guiding immunization activities. That enzyme immunoassay is the most convenient method and approach for detecting the rubella virus. 

Latex agglutination assays detect Rubella-specific antibodies by generating visible clumping (agglutination) of latex particles coated with Rubella antigens when combined with the patient's serum or plasma. While quick and easy, these tests may have lesser sensitivity than other procedures and are frequently employed as screening tests rather than confirmatory diagnoses.

By application, the segment can be further bifurcated into Hospitals and laboratories.

The hospital segment dominates the application segment of the global rubella diagnostic testing market, with a 40% market share in 2023, and is expected to develop rapidly during the forecast period. Hospitals play an important role in Rubella diagnostic tests, especially in the clinical management of patients who come with Rubella-like symptoms or consequences. Rubella diagnostic tests are routinely conducted in various hospital departments, including emergency rooms, pediatric wards, obstetrics and gynecology departments, and infectious disease units. Patients suspected of having Rubella infection may receive diagnostic testing as part of their clinical evaluation, with the results used to guide treatment options, infection control measures, and patient counseling.

Additionally, the segment's rise is linked to increased hospitals and the introduction of technology that provides quick results. Furthermore, government financing and legislation drive significant growth in the healthcare industry. The increasing prevalence of infectious diseases is expected to drive market expansion shortly. As a result, these factors are projected to drive the expansion of rubella diagnostics over the forecast period.

Rubella diagnostic testing relies heavily on diagnostic laboratories, including clinical and reference labs. These laboratories have the requisite infrastructure, apparatus, and competence to perform various Rubella diagnostic tests, including serological and molecular assays. Rubella testing services in the laboratory may be provided as part of routine clinical testing menus, specific infectious disease testing panels, or prenatal screening programs. Laboratory professionals conduct Rubella testing, analyze the results, and report them to healthcare providers for patient management and public health surveillance.

Recent Developments

• April 2024- Abbott (NYSE: ABT) received FDA approval for its TriClip™ transcatheter edge-to-edge repair (TEER) device, which is intended to treat tricuspid regurgitation (TR) or a leaking tricuspid valve.
• March 2024- Siemens Healthineers planned to close Fast Track Diagnostics.